NCT07489989
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
- Locations
-
- Chinese PLA General Hospital Beijing, Beijing Municipality, China
Clinical trial condition
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Explore clinical trials studying Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL). Study availability and eligibility vary by location and protocol.
2 public trials
1 recruiting study
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) trial results
Not Yet Recruiting
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT07601607
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
- Locations
-
- Sun yat-sen university cancer center Guangzhou, Guangdong, China